These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25390822)

  • 1. Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications.
    Baker J; OʼHara KM
    JAAPA; 2014 Dec; 27(12):10-7. PubMed ID: 25390822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J; Dufrene SL; Okulicz JF
    Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective.
    Conniff J; Evensen A
    J Am Board Fam Med; 2016; 29(1):143-51. PubMed ID: 26769887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(6):520. PubMed ID: 26977839
    [No Abstract]   [Full Text] [Related]  

  • 7. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PrEParing for Preexposure Prophylaxis.
    Zappas MP; Foreman RM
    J Dr Nurs Pract; 2020 Mar; 13(1):3-8. PubMed ID: 32701461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
    JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emtricitabine + tenofovir to prevent HIV transmission. More evaluation needed.
    Prescrire Int; 2013 Jul; 22(140):178-81. PubMed ID: 23951592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV Prevention: Opportunities and Challenges.
    Marrazzo JM
    Top Antivir Med; 2017; 24(4):123-126. PubMed ID: 28208119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
    Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA;
    AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-exposure prophylaxis is effective at preventing HIV in high risk gay men, study shows.
    Mayor S
    BMJ; 2015 Sep; 351():h4860. PubMed ID: 26359448
    [No Abstract]   [Full Text] [Related]  

  • 14. Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention.
    Rowan SE; Patel RR; Schneider JA; Smith DK
    Lancet HIV; 2021 Feb; 8(2):e114-e120. PubMed ID: 33128874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
    Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
    Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E; Cohan D
    AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
    Mugo PM; Sanders EJ; Mutua G; van der Elst E; Anzala O; Barin B; Bangsberg DR; Priddy FH; Haberer JE
    AIDS Behav; 2015 May; 19(5):794-801. PubMed ID: 25432877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
    Haberer JE
    Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
    Thomson KA; Baeten JM; Mugo NR; Bekker LG; Celum CL; Heffron R
    Curr Opin HIV AIDS; 2016 Jan; 11(1):18-26. PubMed ID: 26417954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis.
    Srinivas N; Cottrell M; Maffuid K; Prince HA; Nelson JAE; White N; Sykes C; Dellon ES; Madanick RD; Shaheen NJ; Gonzalez D; Kashuba ADM
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.